Abstract
AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.
RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.
CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.
| Original language | English |
|---|---|
| Journal | Future Oncology |
| DOIs | |
| Publication status | Published - Mar 19 2019 |
Fingerprint
Cite this
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. / Caffo, Orazio; Facchini, Gaetano; Biasco, Elisa; Ferraù, Francesco; Morelli, Franco; Donini, Maddalena; Buttigliero, Consuelo; Calvani, Nicola; Guida, Annalisa; Chiuri, Vincenzo Emanuele; Basso, Umberto; Mucciarini, Claudia; Conteduca, Vincenza; Rossetti, Sabrina; Veccia, Antonello; Maines, Francesca; Kinspergher, Stefania; De Giorgi, Ugo.
In: Future Oncology, 19.03.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer
AU - Caffo, Orazio
AU - Facchini, Gaetano
AU - Biasco, Elisa
AU - Ferraù, Francesco
AU - Morelli, Franco
AU - Donini, Maddalena
AU - Buttigliero, Consuelo
AU - Calvani, Nicola
AU - Guida, Annalisa
AU - Chiuri, Vincenzo Emanuele
AU - Basso, Umberto
AU - Mucciarini, Claudia
AU - Conteduca, Vincenza
AU - Rossetti, Sabrina
AU - Veccia, Antonello
AU - Maines, Francesca
AU - Kinspergher, Stefania
AU - De Giorgi, Ugo
PY - 2019/3/19
Y1 - 2019/3/19
N2 - AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.
AB - AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.
U2 - 10.2217/fon-2018-0715
DO - 10.2217/fon-2018-0715
M3 - Article
C2 - 30887825
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
ER -